The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226.
about
Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behaviorA neuropeptide ligand of the G protein-coupled receptor GPR103 regulates feeding, behavioral arousal, and blood pressure in miceAgonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226Central neuropeptide Y receptors are involved in 3rd ventricular ghrelin induced alteration of colonic transit time in conscious fed ratsOn the role of thymopoietins in cell proliferation. Immunochemical evidence for new members of the human thymopoietin family[(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptorsVascular pharmacology of BIIE0246, the first selective non-peptide neuropeptide Y Y(2) receptor antagonist, in vivoThe functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y1 receptorChicken neuropeptide Y receptor Y2: structural and pharmacological differences to mammalian Y2(1).A Y2 receptor mimetic aptamer directed against neuropeptide Y.Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans.The involvement of norepinephrine, neuropeptide Y, and nitric oxide in the cutaneous vasodilator response to local heating in humans.Neuropeptide Y directly inhibits neuronal activity in a subpopulation of gonadotropin-releasing hormone-1 neurons via Y1 receptors.High-affinity neuropeptide Y receptor antagonists.G protein-coupled receptors function as logic gates for nanoparticle binding and cell uptake.The neuropeptide Y Y1 receptor knockdown modulates activator protein 1-involved feeding behavior in amphetamine-treated rats.The neuropeptide y y(1) receptor: a diagnostic marker? Expression in mcf-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts.BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonistEffects of a selective neuropeptide Y Y(1) receptor antagonist BIBP 3226 on double peaked vasoconstrictor responses to periarterial nerve stimulation in canine splenic arteries.NPY presynaptic actions are reduced in the hypothalamic mpPVN of obese (fa/fa), but not lean, Zucker rats in vitro.Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226.Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226.Central hypotensive effects of neuropeptide Y are modulated by endothelial nitric oxide synthase after activation by ribosomal protein S6 kinaseNonpeptide ligands of neuropeptide FF: current status and structural insights.Neuropeptide Y and gamma-melanocyte stimulating hormone (gamma-MSH) share a common pressor mechanism of action.Neuropeptide Y and neurovascular control in skeletal muscle and skinNeuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development.Neuropeptide Y receptors: how to get subtype selectivityNeuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and c-AMP response element-binding protein in phenylpropanolamine-treated rats.Neuropeptide Y receptors: a promising target for cancer imaging and therapy.What's in a Name? Roles of RFamide-Related Peptides Beyond Gonadotrophin Inhibition.[³H]UR-MK136: a highly potent and selective radioligand for neuropeptide Y Y₁ receptors.Receptors for NPY and PACAP differ in expression and activity during adipogenesis in the murine 3T3-L1 fibroblast cell lineRe-evaluation of receptor-ligand interactions of the human neuropeptide Y receptor Y1: a site-directed mutagenesis study.Neuropeptide Y receptor expression in human primary ovarian neoplasms.Pharmacological characterization of cloned chicken neuropeptide Y receptors Y1 and Y5.Novel analogues of neuropeptide Y with a preference for the Y1-receptor.SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist.Synthesis and characterization of a selective peptide antagonist of neuropeptide Y vascular postsynaptic receptors.NPY receptor subtype in the rabbit isolated ileum
P2860
Q24309148-6C01BFF7-08A4-4943-8189-86708FDBBB59Q24544218-4D42FCCB-317F-4450-ACCE-75C52040EA26Q24673730-D43CC6ED-C7C4-4165-A290-4C5A36D5F080Q24800610-D4302543-9667-4E64-96EC-558F16CF4935Q28140950-0884EEAB-823C-4717-A83A-4B661F55FD6DQ28343949-46674159-C63C-4D6A-9733-8AEA7CE02BC0Q28345465-8A5FD747-6465-46AE-BEBA-B57F02F08C63Q28379256-B95E84B8-2324-4EBD-A33B-43E71512A387Q30962310-B2457A28-ABCA-403A-945B-DE6D3B79C730Q31033093-E0170A47-0830-40BE-86DB-D15C47424315Q31067603-E953405C-B6FF-4228-966A-1945D0BBA4B7Q33335061-559101DB-254D-45E6-AF59-D4C67EC8794CQ33874528-6ECAED99-EB92-4106-A8EB-056B4B08C2A3Q33883621-6970FAC4-F9F5-4959-A63B-1D24ADF89978Q33934981-2401DCBE-E527-41AA-90F8-691ED929E9B6Q34480148-D55BC193-60A5-4305-9A0E-43D579465684Q34510673-2C049109-B742-49FC-BFCF-FA4F2DD20B03Q35042022-21E3D714-B779-4D07-9CF0-418E30487D24Q35042557-9EFC9D13-7E04-4021-A78C-FE9F029A7923Q35046263-B4FC0841-E385-4E52-9B95-539013225237Q35872833-53665577-655E-43C0-BEF1-32B89DB735FAQ35873194-2326DF41-2932-4332-BD87-E629F30DABA5Q36382987-50A5A805-2CDF-479F-BE33-DE64310859DBQ36712265-76EC551C-1ABB-41E3-B66A-AC54DE85928AQ37272844-0440FFD1-234B-4A30-A5F1-AAEF6A952796Q37337568-6E1FA48D-BC2C-46C5-8820-95A1818A9E16Q37847125-E4E66918-BB72-4045-B3C0-B9FC07C3AC98Q38079230-AEFB934C-2127-4A00-ADED-C2415FC74B60Q38320911-AAE9A4FE-6EFE-4D5E-97EF-CD67D235BE34Q38713678-5FC2349C-6A5D-42F5-8AE4-7892D5AEF63BQ38883710-3CF78B3C-0C54-48BC-9820-23ABCF5D0A26Q39512007-B023B900-303C-4C6B-88FB-8CE0A22E572EQ39855464-DD21004E-4377-4ABF-9EA1-D7BFC6DD6F6CQ40385965-3AFC1247-D51A-4EC8-80AB-5DF9611661C3Q40614679-030D4C26-27D1-4561-9644-402A5FFF4B0AQ40724986-0F378C3B-2A61-4479-A9EA-38614955ADB8Q40805267-C2034A89-3A36-45C2-AA53-161769D51B4AQ41351619-E67F78FA-C3E3-4FFC-9438-8C0765D24EF2Q41784280-24B3B1D4-03A0-441A-8A34-C2BC3390C7B9Q41900322-4ECA7CDB-A2C6-4EE7-BEC9-FBD12BABEABC
P2860
The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226.
description
1994 nî lūn-bûn
@nan
1994 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
The first highly potent and se ...... receptor antagonist: BIBP3226.
@ast
The first highly potent and se ...... receptor antagonist: BIBP3226.
@en
The first highly potent and se ...... receptor antagonist: BIBP3226.
@nl
type
label
The first highly potent and se ...... receptor antagonist: BIBP3226.
@ast
The first highly potent and se ...... receptor antagonist: BIBP3226.
@en
The first highly potent and se ...... receptor antagonist: BIBP3226.
@nl
prefLabel
The first highly potent and se ...... receptor antagonist: BIBP3226.
@ast
The first highly potent and se ...... receptor antagonist: BIBP3226.
@en
The first highly potent and se ...... receptor antagonist: BIBP3226.
@nl
P2093
P1476
The first highly potent and se ...... receptor antagonist: BIBP3226.
@en
P2093
Beck-Sickinger AG
Eberlein W
Entzeroth M
Wieland HA
P356
10.1016/0014-2999(94)90822-2
P407
P577
1994-12-01T00:00:00Z